Oncology Institute (DFPH) Income towards Parent Company (2020 - 2026)

Oncology Institute (DFPH) has 7 years of Income towards Parent Company data on file, last reported at -$2.5 million in Q1 2026.

• Quarterly Income towards Parent Company rose 87.28% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.5 million (up 32.39% YoY) and the FY2025 annual result came in at -$60.6 million, up 6.27% from the prior year.
• Income towards Parent Company improved to -$2.5 million in Q1 2026, from -$7.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $19.3 million in Q1 2022 to a low of -$30.0 million in Q1 2023.
• A 5-year average of -$12.4 million and a median of -$16.1 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 2036.35% — and 2023, when it slumped 551.42%.
• Tracing DFPH's Income towards Parent Company over 5 years: stood at -$11.0 million in 2022, then plunged by 70.38% to -$18.8 million in 2023, then increased by 29.71% to -$13.2 million in 2024, then jumped by 43.04% to -$7.5 million in 2025, then soared by 66.81% to -$2.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$2.5 million (Q1 2026), -$7.5 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.